These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 9700338)

  • 1. Rare diseases and "orphan" drugs.
    Hillcoat BL
    Med J Aust; 1998 Jul; 169(2):69-70. PubMed ID: 9700338
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug development. Orphan drug windfalls?
    Gershon D
    Nature; 1992 Jan; 355(6359):381. PubMed ID: 1734267
    [No Abstract]   [Full Text] [Related]  

  • 3. Creating the costliest orphan. The Orphan Drug Act in the development of Ceredase.
    Goldman DP; Clarke AE; Garber AM
    Int J Technol Assess Health Care; 1992; 8(4):583-97. PubMed ID: 1464480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Competing for the treasure in exceptions.
    Cox TM
    Am J Hematol; 2013 Mar; 88(3):163-5. PubMed ID: 23400870
    [No Abstract]   [Full Text] [Related]  

  • 5. Current status of orphan disease drug development.
    Thoene JG
    Curr Opin Pediatr; 1994 Apr; 6(2):209-12. PubMed ID: 8032402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Why Genzyme can charge so much for Cerezyme.
    Anand G
    Wall St J (East Ed); 2005 Nov; ():A15. PubMed ID: 16502533
    [No Abstract]   [Full Text] [Related]  

  • 7. From the Food and Drug Administration.
    Nightingale SL
    JAMA; 1991 Jun; 265(22):2934. PubMed ID: 1903461
    [No Abstract]   [Full Text] [Related]  

  • 8. Management of neuronopathic Gaucher disease: a European consensus.
    Vellodi A; Bembi B; de Villemeur TB; Collin-Histed T; Erikson A; Mengel E; Rolfs A; Tylki-Szymanska A;
    J Inherit Metab Dis; 2001 Jun; 24(3):319-27. PubMed ID: 11486896
    [No Abstract]   [Full Text] [Related]  

  • 9. [Treatment of type 1 Gaucher's disease. Still a long way to go].
    Pérez Calvo JI; Giraldo Castellano P
    Med Clin (Barc); 2000 May; 114(20):774-6. PubMed ID: 10923324
    [No Abstract]   [Full Text] [Related]  

  • 10. In brief: Taliglucerase (Elelyso) for Gaucher disease.
    Med Lett Drugs Ther; 2012 Jul; 54(1394):56. PubMed ID: 22966489
    [No Abstract]   [Full Text] [Related]  

  • 11. Uncertain miracle: a biotech drug extends a life, but at what price? For Ms. Lees, treatment bill now totals $7 million; her bones keep crumbling; guilt of another $1,400 day.
    Wall St J (East Ed); 2005 Nov; ():A1, A15. PubMed ID: 16502532
    [No Abstract]   [Full Text] [Related]  

  • 12. Approval times for supplemental indications for recombinant proteins.
    Gosse ME; Nelson TF
    Nat Biotechnol; 1997 Feb; 15(2):130-4. PubMed ID: 9035135
    [No Abstract]   [Full Text] [Related]  

  • 13. Rare diseases and orphan drugs.
    Daina E
    Lancet; 1994 Jun; 343(8912):1560-1. PubMed ID: 7911879
    [No Abstract]   [Full Text] [Related]  

  • 14. Orphan drugs and orphan tests in the USA.
    Thoene JG
    Community Genet; 2004; 7(4):169-72. PubMed ID: 15692190
    [No Abstract]   [Full Text] [Related]  

  • 15. When everyone is an orphan: against adopting a U.S.-styled orphan drug policy in Canada.
    Herder M
    Account Res; 2013; 20(4):227-69. PubMed ID: 23805831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EMEA approves OGS drug rejected by FDA.
    Mitchell P
    Nat Biotechnol; 2002 Sep; 20(9):858-9. PubMed ID: 12205490
    [No Abstract]   [Full Text] [Related]  

  • 17. Federal 340B Program Payment Scheme for Drugs Designated As Orphan Products: Congressional Clarification Needed to Close the Government-Industry Revolving Door.
    Yang YT; Chen B; Bennett CL
    J Clin Oncol; 2016 Dec; 34(36):4320-4322. PubMed ID: 27998222
    [No Abstract]   [Full Text] [Related]  

  • 18. Gaucher disease: assessment of skeletal involvement and therapeutic responses to enzyme replacement.
    Hermann G; Pastores GM; Abdelwahab IF; Lorberboym AM
    Skeletal Radiol; 1997 Dec; 26(12):687-96. PubMed ID: 9453101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enzyme replacement therapy "drug holiday": results from an unexpected shortage of an orphan drug supply in Australia.
    Goldblatt J; Fletcher JM; McGill J; Szer J; Wilson M
    Blood Cells Mol Dis; 2011 Jan; 46(1):107-10. PubMed ID: 20684886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Orphan drug product regulation--United States.
    Haffner ME
    Int J Clin Pharmacol Ther; 2002 Feb; 40(2):84-8. PubMed ID: 11862977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.